{"title":"管理SARS-CoV-2感染是淋巴系统恶性肿瘤患者的主要挑战:需要明确的治疗策略。","authors":"Tarun Sahu, Henu Kumar Verma, Bhaskar Lvks","doi":"10.5501/wjv.v11.i4.204","DOIUrl":null,"url":null,"abstract":"<p><p>Patients with lymphoid malignancies are at a higher risk of coronavirus disease 2019 (COVID-19) infection due to their immunocompromised state and results in higher mortality rates in these patients. Anti-CD 20 therapy is one of the leading causes of immunosuppression that worsens in COVID-19 cases. COVID-19 vaccines, on the other hand, appear to be less beneficial to these patients. App-ropriate treatment and recommendations are required for these COVID-19 patients with lymphoid malignancies.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"11 4","pages":"204-207"},"PeriodicalIF":0.0000,"publicationDate":"2022-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a4/3b/WJV-11-204.PMC9372783.pdf","citationCount":"2","resultStr":"{\"title\":\"Management of SARS-CoV-2 infection is a major challenge in patients with lymphoid malignancies: Warrants a clear therapeutic strategy.\",\"authors\":\"Tarun Sahu, Henu Kumar Verma, Bhaskar Lvks\",\"doi\":\"10.5501/wjv.v11.i4.204\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Patients with lymphoid malignancies are at a higher risk of coronavirus disease 2019 (COVID-19) infection due to their immunocompromised state and results in higher mortality rates in these patients. Anti-CD 20 therapy is one of the leading causes of immunosuppression that worsens in COVID-19 cases. COVID-19 vaccines, on the other hand, appear to be less beneficial to these patients. App-ropriate treatment and recommendations are required for these COVID-19 patients with lymphoid malignancies.</p>\",\"PeriodicalId\":61903,\"journal\":{\"name\":\"世界病毒学杂志(英文版)\",\"volume\":\"11 4\",\"pages\":\"204-207\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-07-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a4/3b/WJV-11-204.PMC9372783.pdf\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"世界病毒学杂志(英文版)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5501/wjv.v11.i4.204\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"世界病毒学杂志(英文版)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5501/wjv.v11.i4.204","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Management of SARS-CoV-2 infection is a major challenge in patients with lymphoid malignancies: Warrants a clear therapeutic strategy.
Patients with lymphoid malignancies are at a higher risk of coronavirus disease 2019 (COVID-19) infection due to their immunocompromised state and results in higher mortality rates in these patients. Anti-CD 20 therapy is one of the leading causes of immunosuppression that worsens in COVID-19 cases. COVID-19 vaccines, on the other hand, appear to be less beneficial to these patients. App-ropriate treatment and recommendations are required for these COVID-19 patients with lymphoid malignancies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
